FDA study highlights misleading labeling by NCIT manufacturers
Since the start of the pandemic, non-contact infrared thermometers (NCITs) have become the primary tool used in public temperature screenings, even though extensive scientific research has proven that they do not produce reliable or accurate temperature readings. Now, an important new study published by the FDA adds to that body of scientific data, demonstrating that non-contact thermometers fail to reliably detect fevers. It also proves that they fall outside of the accuracy specifications advertised in manufacturers’ instructions and labeling for proper usage. In sharp contrast, the Exergen TemporalScanner’s accuracy is supported by more than 100 peer-reviewed published clinical studies.
The study was undertaken because of the NCIT’s high probability for producing false negative readings close to the CDC fever threshold. It also sought to evaluate their adherence to FDA labeling requirements and in both cases, the non-contact thermometers failed. The study tested six different commercially available NCIT models among a large sample of 1,113 adult subjects, 93% between 18 and 30 years old and 7% older than 30, a population heavily weighted to healthier individuals, based on age. With 10 units per model, 60 NCITs were tested. and readings were compared to those taken with a reference oral thermometer.
The mean difference between the reference thermometer and the NCIT measurements for under- and over-reporting varied widely by model. Depending on the device, 48% to 88% of the individual temperature measurements fell outside the labeled accuracy stated by the manufacturers. These false readings were obtained in a highly controlled environment that carefully managed all possible variables that could contribute to a high or low reading, making the results even more significant.
“We agree with the FDA’s assessment that non-contact thermometers are inaccurate and fail to meet guidelines for accurate labeling and marketing. We are seeing retailers removing NCITs from their shelves, but all manufacturers should be held accountable by the FDA,” said Francesco Pompei, Ph.D., CEO of Exergen Corporation.